AstraZeneca PLC vs Eli Lilly & Co.
AZN vs LLY — side-by-side comparison from reported financials. AZN leads 3, LLY leads 8 of 11 comparable metrics.
AstraZeneca PLC
AZN · Healthcare
$159.20+0.26%Solid
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | AZN | LLY |
|---|---|---|
| Price | $159.20 | $1 177.20 |
| Market cap | $247B | $1.05T |
| Revenue (TTM) | $58.7B | $79.7B |
| Revenue growth | +9.8% | +31.7% |
| Net margin | 17.4% | 33.5% |
| Free cash flow | $10.7B | $18.2B |
| Net cash (debt) | ($27.4B) | ($35.2B) |
| 1-year price return | -6.4% | +37.6% |
| P/E | 23.4 | 41.6 |
| P/E vs own history (cheap-side %) | 65% | 88% |
| Dividend yield | 2.01% | 0.52% |
| Return on equity | 22% | 93% |
| Altman Z-score | 2.16 | 7.10 |
| CV checks passed | 11 of 11 | 11 of 11 |
| Employees | 96,100 | 50,000 |
Full résumé-style profiles: AZN CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.